[Myasthenia gravis and intestinal resection: is dehiscence likely to occur?].
Experimental and clinical data have proved that anticholinesterase drugs are responsible for vigorous peristaltic contractions and for an increase of the intraluminal pressure, because they determine muscarinic effects on the smooth muscle of the intestine both in small and large intestine. Therefore, a greater incidence of intestinal anastomotic disruption has been supposed when anticholinesterases are used both in the early postoperative period, to reverse curarization, and in myasthenic patients. The authors report a case of a patient with myasthenia gravis who received maximal doses of pyridostigmine and underwent left hemicolectomy and small intestine resection and afterwards total colectomy in order to treat a sigmoid perforated diverticulitis. In the postoperative course an anastomotic leak developed after both surgical operations. The authors believe that pyridostigmine could have had an important role in the pathogenesis of the leak and assert that, when an intestinal resection has to be performed in a myasthenic patient, it could be useful to reduce in the preoperative period the administration of anticholinesterase drugs and always perform a protective ileostomy.
Li Destri
G
G
Dipartimento di Scienze Chirurgiche, Trapianti d'Organo e Tecnologie Avanzate, Policlinico Universitario, Università degli Studi di Catania, Catania, Italy. g.lidestri@unict.it
Scilletta
B
B
Latino
R
R
Di Cataldo
A
A
D000368:Aged; D000714:Anastomosis, Surgical / Q000009:adverse effects*; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D003082:Colectomy; D004238:Diverticulitis / Q000601:surgery*; D004241:Diverticulum, Colon / Q000601:surgery*; D006801:Humans; D007077:Ileal Diseases / Q000601:surgery*; D007081:Ileostomy; D007412:Intestinal Fistula / Q000601:surgery*; D007416:Intestinal Perforation / Q000601:surgery*; D008297:Male; D009157:Myasthenia Gravis / Q000150:complications* / Q000188:drug therapy; D011300:Preoperative Care; D011729:Pyridostigmine Bromide / Q000008:administration & dosage / Q000627:therapeutic use; D012810:Sigmoid Diseases / Q000601:surgery*; D013529:Surgical Wound Dehiscence / Q000209:etiology*
D002800:Cholinesterase Inhibitors; D011729:Pyridostigmine Bromide